Background: Spinal muscular atrophy is a rare genetic disease, which primarily
INTRODUCTION
Spinal muscular atrophy (SMA)-a destructive motor neuron (MN) disorder which occurs in infancy-is primarily caused by survival motor neuron 1 gene (SMN1) mutations. SMN1 and SMN2 are near identical genes encoding the survival motor neuron (SMN) protein [1, 2] . Mutations in the SMN1 gene lead to the reduction or loss of SMN protein expression, causing motor axon defects and motor neuron (MN) death [1, 3] .
Generally, reduced SMN protein expression is believed to cause the death of lower motor neurons, thereby inducing denervation and skeletal muscle atrophy [3] .
The major clinical characteristic of SMA is the selective and progressive loss of MNs via apoptosis, although the factors, which trigger this loss, remain unknown [4] .
Multiple interacting factors have been implicated in MN lesions, including mitochondrial dysfunction, excitotoxicity, protein aggregation and misfolding, defective axonal transport, dysregulated transcription and RNA processing, apoptosis, and oxidative stress [1, 5, 6] .
While SMA has traditionally been classified as a pure lower motor neuron disease, it is becoming clear that supplementary cells and tissue types are particularly susceptible to decreased SMN expression. Current therapeutic strategies focus on increasing SMN expression; however, developing an effective treatment for all affected cells remains a challenge. Targeting cells other than MNs in order to successfully provide therapy for SMA is possible via the intramuscular administration of adeno-associated virus serotype 9 (AAV9) carrying the SMN gene, which can enter the spinal cord via retrograde transport and transduce multiple organs in peripheral tissues. Indeed, gene therapy approaches using AAV9-SMN vectors have entered Phase I clinical trials and are highly promising. However, limitations associated with this treatment highlight the need for combined therapies that rescue both MN function and increase SMN levels. As such, the identification and characterization of SMArelated pathologies that occur across tissues and affected cells is crucial for the development of novel SMA therapeutic strategies [1, 8] Oxidative stress is an instrumental factor in the pathogenesis of many neurodegenerative diseases [9] , and typically occurs when a cell fails to cope with excess levels of reactive oxygen species (ROS), resulting in toxic effects facilitated by peroxides and free radicals. ROS is formed via uncoupled nitric oxide synthase and nicotinamide adenine dinucleotide phosphate oxidase [10] . Antioxidants are important for the removal of ROS before they become problematic. If ROS is not removed, chronic oxidative stress can lead to DNA damage and the subsequent promotion of cell death [10] .
The involvement of oxidative stress in SMA pathogenesis remains unclear.
For instance, nicotinamide adenine dinucleotide phosphate levels are reportedly elevated in the cardiac tissue of (SMNΔ7) mice, but are unchanged in the spinal cord [11] . Moreover, severe mitochondrial oxidative stress is elicited by SMN breakdown in human embryonic stem cell-derived MN progenitors, and antioxidant treatment with N-acetylcysteine prevents the apoptotic death of MNs [8] .
Oprea et al. reported PLS3, as an SMA modifier, qualifying it as a promising therapeutic target [2] . In agreement with this, PLS3 gene overexpression has been shown to refine axonal outgrowth in SMN-deficient MNs in a zebrafish model of SMA as well as in MNs cultured from mouse embryos [1, 5] . Several studies have reported an actin-independent role of PLS3 in SMA modification [5, 12] ; however, investigations on the potential protective role of PLS3 against oxidative stress have not been performed. Some reports have described the involvement of oxidative damage in the neurodegenerative process of SMA, and neuroprotection is considered to be an effective treatment option for many central nervous system disorders, including neurodegenerative diseases such as SMA [5, 6] . Therefore, a therapeutic strategy involving antioxidant gene delivery could provide significant protection for MNs in SMA [1] . This study is, to the best of our knowledge, the first to address whether overexpression of PLS3 using a lentiviral vector (LV) in an in vitro model of SMA could reduce oxidative stress and thus protect MN-like cells.
MATERIALS AND METHODS

Cell culture
A hybrid mouse MN-neuroblastoma cell line, NSC-34, was purchased from "Cedarlane Laboratories (CLU 140-A; thru Tebu-Bio, Le Perray en Yvelines, France) and cultured as previously reported [25] . The human embryonic kidney cell line, HEK293T, (293T ATCC CRL-3216) was also used. All cell lines were cultured in tissue culture flasks (CELLSTAR, Greiner, Germany) in Dulbecco's Modified Eagle's Medium (Lonza, BE12-741F) with 10% heat-inactivated Fetal Bovine Serum (Biosera, FB-1001), 100 U/mL of penicillin and 100 μg/mL streptomycin (Invitrogen, Paisley, UK). Cells were incubated at 37°C and in 5% CO2 with a 95% humidified air atmosphere. Cells were subcultivated at a ratio of 1:8 twice weekly by removing medium, adding 2 mL of trypsin (Sigma, 9002-07-7) supplemented with 0.5 mM ethylenediaminetetraacetic acid (EDTA, Sigma, 6381-92-6) in phosphate-buffered saline (PBS), and incubating for several minutes. When cells detached, the enzymatic activity of trypsin was halted by adding excess culturing medium. All experiments were performed on passage 15─20. Once cells reached approximately 80% confluency, they were either harvested or left for passaging.
LVs
All LVs were provided by Prof. Mimoun Azzouz at the University of Sheffield, UK and were generated in his laboratory. LVs expressing PLS3 were constructed by extracting PLS3 gene out of the vector (-pƈ DNA3.1-PLS3-V5-His6) and then cloned it into the (SIN-PGK-cPPT-GDNF-WHV) LV; LV titer was 2.55 ×
10
8 TU/mL. The LV expressing LacZ was generated using cDNA for "betagalactosidase (LacZ)" and "humanistic GDNF encompassing Kozak sequence (636 bp fragment, position 1-4851 and 1-151)" (GenBank L19062 and L19063 accession numbers), thus preventing secretion of the trophic factor [26] . These cDNAs were replicated in the SIN-W-PGK transfer vector. [27] Transduction of HEK293T and NSC-34 cells with LV-PLS3
HEK239T and NSC-34 cells were plated in a 6-well plate at a density of 150 000-250 000 cells/well in 2 mL of medium and incubated overnight at 37°C in a 
Statistical analysis
Data were assessed using a one-way ANOVA and results are presented as the average measurements per plate ± standard deviation (SD).
Graph-Pad Prism software version 7.0 was used to analyze the data. A one-way ANOVA was utilized to compare the variance between untreated and treated cells. P < 0.05 was considered significantly different.
RESULTS
LVs mediate efficient overexpression of PLS3 in cell lines
Human embryonic kidney (HEK293T) and NSC-34 MN-like cells transduced with an LV carrying the PLS3 gene (LV/PLS3) exhibited a significant rise in PLS3 expression compared to non-transduced (NT) control cells.
PLS3 protein levels in HEK293T cells transduced with LV-PLS3
Transduction of HEK293T cells was performed using the LV-PLS3 vector at different multiplicities of infection (MOIs; 5, 20, and 40). The experiment was repeated three times (n = 3) and demonstrated that LV-PLS3 transduction successfully induced PLS3 overexpression in HEK293T cells (Fig 1) . Western blot analysis (Fig   1a) revealed the appearance of a protein band (70-kDa), indicative of PLS3 in all three conditions. A 50-kDa band was detected using western immunoblotting for α-tubulin, which served as a loading control. In non-transduced (NT) cells, endogenous PLS3 expression was undetectable. Densitometry analysis of western blots revealed a correlation between increased transgene PLS3 expression and the MOI of the LV used for transduction. PLS3 expression was maximum 5 days after transduction with MOI 20, showing a 7-fold increase compared to NT cells (Fig 1b) . Moreover, a previous study reported no signs of toxicity or any apparent differences in cellular growth rate, even after transduction with higher MOIs (data not provided) [13] .
Transduction efficiency of LV-PLS3 in HEK293T cells
Immunofluorescence was performed to evaluate the expression and localization of PLS3 in HEK293T cells 72 h after transduction with ( LV-PLS3 ;
MOIs 5 & 20) compared to NT HEK293T cells (Fig 2) . that the experiment was After oxidative stress induction, the durability of cells transduced with LѴ-PLS3 was observed to increase by approximately 92% (P value < 0.001, n =4) in comparison to NT cells and 61% (P value < 0.01, n = 4) in comparison to LѴ-lacZtransduced cells (Fig 5) . Previous studies have confirmed that 6 h of menadione administration in a redox cycling system is sufficient to increase ROS within numerous subcellular chambers [14] . In this study, PLS3 overexpression in serum- 
DISCUSSION
This study attempted to assess the potential PLS3 anti-oxidative effect of in an in vitro SMA model. In order to do so, a lentivirus was used to confer stable PLS3 overexpression in NSC-34 cells. Oxidative stress was then induced by depriving cells of serum and the levels of intracellular oxidative mediators were assessed using a fluorimetric assay (DCF). LVs were selected as gene delivery vectors due to their ability to efficiently transfer genes to cells of the CNS in vitro and in vivo, and because they can transduce both dividing and non-dividing cells, including neurons [15] . In addition, it has been reported that LVs can efficiently deliver genes to different primary neuron types across a broad range of species, including humans, resulting in long-term gene expression [16, 17] . Two cell lines were used (HEK293T and NSC-34) to assess LV transduction efficiency, and NSC-34 MN-like cells were further selected as an in vitro model of SMA. Ideally, SMA pathophysiology should be studied in in vitro cultures of primary MNs [2, 17, 18, 19] . However, due to decreased MN culture yields, the NSC-34 cell line is considered a suitable alternative to MN cultures and has been widely used to model MN diseases [13] . Indeed, NSC-34
MN-like cells differentiate via a process resembling that of primary MNs, comprise extended neurites, and express MN-specific markers [20] .
The therapeutic potential of the PLS3 gene has previously been demonstrated using a tissue culture-based example of SMN1-associated SMA [2, 18] . insufficiency promotes the reactivity of astrocyte, but that this effect is not elicited via an oxidative stress-mediated process [21] .
While several factors, including oxidative stress, contribute to various ageaffiliated neurodegenerative disorders, their involvement in the pathogenesis of SMA remains unclear. One potential interpretation for this variation is the age of onset for various age-linked diseases, where oxidative stress could increase over time in order to alter neurons in a specific region. As SMA Type I occurs in infancy, neurons are only exposed to stressful surroundings for a brief amount of time. Moreover, for the reduction of stress and cell loss, SMN-deficient cells may utilize endogenous mechanisms.
In the current study, PLS3 overexpression did not significantly reduce oxidative stress, nor did it obviously alter NSC-34 survival or morphology. These findings also reveal that other antioxidant genes associated with this pathway were unable to independently induce neuroprotection. One explanation for the lack of effect is the possibility that cells were not sufficiently mature, prohibiting the ability to reduce oxidative stress under the current circumstances. Furthermore, the use of primary MN cultures, rather than the NSC-34 cell line, would be more appropriate to elucidate mechanisms underlying cell protection within SMA and other MN disorders. Nonetheless, NSC-34 cells continue to be fitting for studies on neuroprotection [22] and neurotoxins [23] , and to explore the outcomes of cerebrolysin [22] . As mentioned, NSC-34 cells display similar properties to MNs when exposed to conditions which promote maturation and differentiation [14] .
Moreover, the NSC-34 cell line could be adopted to study the pathophysiological features of amyotrophic lateral sclerosis-another neurodegenerative MN disease.
Thus, while this cell line was not ideal for the current study, it appears well-suited as a therapeutic screening tool and for specialized experiments.
CONCLUSIONS
In this study, PLS3 overexpression in NSC-34 MN-like cells did not readily reduce serum deprivation-induced oxidative stress levels. These findings do not, however, exclude the possibility that PLS3 exerts an anti-oxidative effect that could not be detected using the current experimental setup. Future investigations using other experimental designs that include primary mouse MNs or human induced pluripotent stem cell-derived MNs from patients with SMA will be useful to determine the full neuroprotective efficacy of PLS3. 
